Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$82,160.00
Sep 20, 2022
-
220969
220969
Install solar power in the therapy center and build a second-floor treatment area
$75,000.00
Sep 15, 2022
For-profit organization
Development of a novel mRNA therapy encoding a hepatokine
995579
This project will involve the development of a proprietary lipid nanoparticle (LNP)-mRNA technology for the safe and effective delivery of mRNA encoding the hepatokine Fibroblast Growth Factor 21 (FGF21) as a hepatic gene therapy to promote weight loss in a diet-induced obesity models.
$114,400.00
Sep 1, 2022
Academia
Early detection of cognitive decline using epigenetic biomarkers in peripheral blood
991333
Such a predictor would enable us to identify those people at greatest risk of developing the disease earlier, when disease modifying therapies are deemed most effective, reducing the need for long-term care and increasing quality of life.
$30,000.00
Sep 1, 2022
Individual or sole proprietorship
Graduate Student Awards in Asthma - Doctoral
167086
To create value-added opportunities for the training, education, and professional development of graduate students, to ensure continued improvement of asthma treatment therapies and progress towards finding a cure for asthma.
$8,334.00
Sep 1, 2022
Individual or sole proprietorship
Graduate Student Awards in Asthma - Master’s
167088
To create value-added opportunities for the training, education, and professional development of graduate students, to ensure continued improvement of asthma treatment therapies and progress towards finding a cure for asthma.
$84,028.00
Sep 1, 2022
Academia
User-requirements for an in-home, augmented reality, physical rehabilitation tool for an aging population
995744
Older adults experience barriers to achieving full postoperative potential during conventional, unsupervised in-home therapy, underscoring the need for innovative rehabilitation tools after total joint replacement (TJR).
$364,903.00
Sep 1, 2022
Government
Digital therapeutics for older adults: using mobile technology to deliver therapies anytime and anywhere
996558
Non-pharmacological interventions centered around lifestyle modifications constitute promising approaches to delay the onset or progression of neurodegenerative diseases impacting cognition. An important challenge for the implementation of such interventions is the ability to deliver them in an accessible PAGE 4 and ecological context. To address these challenges, mobile technologies have been increasingly used over the past decade to provide health-related assessments or interventions for older adults in their own living environment. The extent to which mobile assessments and interventions can be integrated to improve health outcomes deserves further investigation. In this project, we will investigate the feasibility and benefits of developing and using a digital phenotyping approach based on remote assessments of sleep and cognition in older adults in the community. We will then explore whether such digital phenotyping may improve the outcomes of a web-based intervention that was developed to promote better sleep and brain health in older adults. This phenotyping approach will allow to collect information on lifestyle factors such as sleep, passively using sensors and actively via short surveys and tasks. Using it, the CRIUGM will run several user-based studies and validate its feasibility with older adults. The integration of measures from the phenotyping approach into the web-based intervention platform is to be used to improve an online sleep-related intervention by tailoring it to the individual’s needs. In addition, it is expected that this integration between remote assessments and intervention will also improve personalized feedback to the user during the intervention, and therefore improve acceptability, engagement, and adherence of older adults to the intervention.
$72,000.00
Sep 1, 2022
For-profit organization
Business Innovation - New sales motion and deployment/fulfilment process to increase referral ratio and 10x Monthly Revenue
995725
This project will allow the firm, with the recently-hired clinical relations manager, marketing associate and marketing COOP, to develop and experiment with new B2B2C commercial deployment and fulfilment processes to increase market penetration of the Tenzr system for Physical Therapy.
$30,000.00
Aug 8, 2022
For-profit organization
Selection and characterization of humanized antibody candidate for the treatment of kappa light chain amyloidosis
994401
There are currently no existing therapies that direct remove these deposits from organs.
$217,397.00
Aug 1, 2022
Academia
Clinical CAR-T cell raman spectroscopy analysis
996027
The approval of chimeric antigen receptor T-cell (CAR-T) therapies has been a major breakthrough for patients with relapsed or refractory blood cancers. However, CAR-T cells are highly complex, live cell therapies, and it has proven difficult to predict CAR-T cell potency.